Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
-
REGULATORY Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
May 13, 2020
-
REGULATORY Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
-
REGULATORY Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
-
BUSINESS Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
-
BUSINESS Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
-
REGULATORY Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
-
REGULATORY Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
-
BUSINESS Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
-
REGULATORY Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
-
BUSINESS Sanofi Japan to Ensure Drug Supplies, Employees’ Safety at the Same Time in COVID-19 Crisis: Chief
April 30, 2020
-
REGULATORY Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
-
BUSINESS Novartis Japan Scraps Sales Offices to Boost Efficiency of Rep Activities
April 27, 2020
-
REGULATORY Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
-
BUSINESS Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
-
BUSINESS Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
-
BUSINESS Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
-
COMMENTARY Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
-
BUSINESS Sawai Curbing Shipments for 2 More Drugs after Nichi-Iko’s Massive Recalls
April 21, 2020
-
BUSINESS Sumitomo Dainippon Chair Sees No Need for Further Consolidation among Japan Drug Makers
April 21, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…